Endocrine disruptors differentially target ATP-binding cassette transporters in the blood-testis barrier and affect leydig cell testosterone secretion in vitro

Toxicological Sciences

Volumn 136, Issue 2, 2013, Pages 382-391

  Dankers, Anita C A ^a   Roelofs, Maarke J E ^a,b   Piersma, Aldert H ^a,b   Sweep, Fred C G J ^c   Russe, Frans G M ^a,b   van den Berg Martin, M ^b   van Duursen, Majorie B M ^b   Masereeuw, Rosalinde ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

ABC transporters; Blood testis barrier; Endocrine disrupting chemicals (EDCs); MA 10 mouse Leydig cells; Steroidogenesis

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; 4,4' ISOPROPYLIDENEDIPHENOL; 7 CHLORO 2 (3 PYRIDYL) ALPHA TETRALONE; 8 BROMO CYCLIC AMP; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 17; ENDOCRINE DISRUPTOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; PHTHALIC ACID 2 ETHYLHEXYL MONOESTER; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; TESTOSTERONE; TETRABROMOBISPHENOL A; VALSPODAR; VERLUKAST;

ANIMAL CELL; ARTICLE; BLOOD TESTIS BARRIER; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; IN VITRO STUDY; LEYDIG CELL; LIQUID CHROMATOGRAPHY; MALE; MDCK CELL; MEMBRANE VESICLE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; RISK ASSESSMENT; SPERMATOGENESIS; STEROIDOGENESIS; TANDEM MASS SPECTROMETRY; TESTOSTERONE RELEASE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ABC TRANSPORTERS; BLOOD-TESTIS BARRIER; ENDOCRINE DISRUPTING CHEMICALS (EDCS); MA-10 MOUSE LEYDIG CELLS; STEROIDOGENESIS.;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-TESTIS BARRIER; CELLS, CULTURED; DOGS; ENDOCRINE DISRUPTORS; HEK293 CELLS; HUMANS; LEYDIG CELLS; MALE; MICE; TESTOSTERONE;

EID: 84890417512     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft198     Document Type: Article

References (40)

1. Ascoli, M. (1981). Characterization of several clonal lines of cultured Leydig tumor cells: Gonadotropin receptors and steroidogenic responses. Endocrinology 108, 88-95.
2. Bart, J., Hollema, H., Groen, H. J., de Vries, E. G., Hendrikse, N. H., Sleijfer, D. T., Wegman, T. D., Vaalburg, W., and van der Graaf, W. T. (2004). The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur. J. Cancer 40, 2064-2070.
3. Bélanger, B., Bélanger, A., Labrie, F., Dupont, A., Cusan, L., and Monfette, G. (1989). Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. J. Steroid Biochem. 32, 695-698.
4. Burgos-Trinidad, M., Youngblood, G. L., Maroto, M. R., Scheller, A., Robins, D. M., and Payne, A. H. (1997). Repression of cAMP-induced expression of the mouse P450 17 alpha-hydroxylase/C17-20 lyase gene (Cyp17) by androgens. Mol. Endocrinol. 11, 87-96.
5. Canton, R. F., Sanderson, J. T., Letcher, R. J., Bergman, A., and van den Berg, M. (2005). Inhibition and induction of aromatase (CYP19) activity by brominated flame retardants in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 88, 447-455.
6. Chen, Z. S., Robey, R. W., Belinsky, M. G., Shchaveleva, I., Ren, X. Q., Sugimoto, Y., Ross, D. D., Bates, S. E., and Kruh, G. D. (2003). Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta- D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 63, 4048-4054.
7. Cheng, C. Y., and Mruk, D. D. (2012). The blood-testis barrier and its implications for male contraception. Pharmacol. Rev. 64, 16-64.
8. Choo, E. F., Leake, B., Wandel, C., Imamura, H., Wood, A. J., Wilkinson, G. R., and Kim, R. B. (2000). Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28, 655-660.
9. Clewell, R. A., Campbell, J. L., Ross, S. M., Gaido, K. W., Clewell, H. J., III, and Andersen, M. E. (2010). Assessing the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response. Toxicol. In Vitro 24, 327-334.
10. Dankers, A. C., Sweep, F. C., Pertijs, J. C., Verweij, V., van den Heuvel, J. J., Koenderink, J. B., Russel, F. G., and Masereeuw, R. (2012). Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 349, 551-563.
11. Devoto, L., Kohen, P., Vega, M., Castro, O., Gonzàlez, R. R., Retamales, I., Carvallo, P., Christenson, L. K., and Strauss, J. F. (2002). Control of human luteal steroidogenesis. Mol. Cell. Endocrinol. 186, 137-141.
12. Enokizono, J., Kusuhara, H., and Sugiyama, Y. (2007). Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol. Pharmacol. 72, 967-975.
13. Ge, R. S., Dong, Q., Sottas, C. M., Papadopoulos, V., Zirkin, B. R., and Hardy, M. P. (2006). In search of rat stem Leydig cells: Identification, isolation, and lineage-specific development. Proc. Natl. Acad. Sci. U.S.A. 103, 2719-2724.
14. Heger, N. E., Hall, S. J., Sandrof, M. A., McDonnell, E. V., Hensley, J. B., McDowell, E. N., Martin, K. A., Gaido, K. W., Johnson, K. J., and Boekelheide, K. (2012). Human fetal testis xenografts are resistant to phthalate-induced endocrine disruption. Environ. Health Perspect. 120, 1137-1143.
15. Jensen, A. A., and Leffers, H. (2008). Emerging endocrine disrupters: Perfluoroalkylated substances. Int. J. Androl. 31, 161-169.
16. Johnson, K. J., Heger, N. E., and Boekelheide, K. (2012). Of mice and men (and rats): Phthalate-induced fetal testis endocrine disruption is speciesdependent. Toxicol. Sci. 129, 235-248.
17. Kitamura, S., Suzuki, T., Sanoh, S., Kohta, R., Jinno, N., Sugihara, K., Yoshihara, S., Fujimoto, N., Watanabe, H., and Ohta, S. (2005). Comparative study of the endocrine-disrupting activity of bisphenol A and 19 related compounds. Toxicol. Sci. 84, 249-259.
18. Kundakovic, M., Gudsnuk, K., Franks, B., Madrid, J., Miller, R. L., Perera, F. P., and Champagne, F. A. (2013). Sex-specific epigenetic disruption andbehavioral changes following low-dose in utero bisphenol A exposure. Proc. Natl. Acad. Sci. U.S.A. 110, 9956-9961.
19. Labrie, F., Luu-The, V., Lin, S. X., Labrie, C., Simard, J., Breton, R., and Bélanger, A. (1997). The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 62, 148-158.
20. Law, R. J., Allchin, C. R., de Boer, J., Covaci, A., Herzke, D., Lepom, P., Morris, S., Tronczynski, J., and de Wit, C. A. (2006). Levels and trends of brominated flame retardants in the European environment. Chemosphere 64, 187-208.
21. Makker, K., Agarwal, A., and Sharma, R. (2009). Oxidative stress & male infertility. Indian J. Med. Res. 129, 357-367.
22. Matsuo, H., Takada, T., Ichida, K., Nakamura, T., Nakayama, A., Ikebuchi, Y., Ito, K., Kusanagi, Y., Chiba, T., Tadokoro, S., et al. (2009). Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population. Sci. Transl. Med. 1, 5ra11.
23. Mazur, C. S., Marchitti, S. A., Dimova, M., Kenneke, J. F., Lumen, A., and Fisher, J. (2012). Human and rat ABC transporter efflux of bisphenol a and bisphenol a glucuronide: Interspecies comparison and implications for pharmacokinetic assessment. Toxicol. Sci. 128, 317-325.
24. Mitchell, R. T., Childs, A. J., Anderson, R. A., van den Driesche, S., Saunders, P. T., McKinnell, C., Wallace, W. H., Kelnar, C. J., and Sharpe, R. M. (2012). Do phthalates affect steroidogenesis by the human fetal testis? Exposure of human fetal testis xenografts to di-n-butyl phthalate. J. Clin. Endocrinol. Metab. 97, E341-E348.
25. Morgan, J. A., Cheepala, S. B., Wang, Y., Neale, G., Adachi, M., Nachagari, D., Leggas, M., Zhao, W., Boyd, K., Venkataramanan, R., et al. (2012). Deregulated hepatic metabolism exacerbates impaired testosterone production in Mrp4-deficient mice. J. Biol. Chem. 287, 14456-14466.
26. Ochsenkuhn, R., and De Kretser, D. M. (2003). The contributions of deficient androgen action in spermatogenic disorders. Int. J. Androl. 26, 195-201.
27. Robey, R. W., To, K. K., Polgar, O., Dohse, M., Fetsch, P., Dean, M., and Bates, S. E. (2009). ABCG2: A perspective. Adv. Drug Deliv. Rev. 61, 3-13.
28. Robillard, K. R., Hoque, T., and Bendayan, R. (2012). Expression of ATPbinding cassette membrane transporters in rodent and human sertoli cells: Relevance to the permeability of antiretroviral therapy at the blood-testis barrier. J. Pharmacol. Exp. Ther. 340, 96-108.
29. Roelofs, M. J., Piersma, A. H., van den Berg, M., and van Duursen, M. B. (2013). The relevance of chemical interactions with CYP17 enzyme activity: Assessment using a novel in vitro assay. Toxicol. Appl. Pharmacol. 268, 309-317.
30. Russel, F. G., Koenderink, J. B., and Masereeuw, R. (2008). Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci. 29, 200-207.
31. Schauer, U. M., Völkel, W., and Dekant, W. (2006). Toxicokinetics of tetrabromobisphenol a in humans and rats after oral administration. Toxicol. Sci. 91, 49-58.
32. Sharlip, I. D., Jarow, J. P., Belker, A. M., Lipshultz, L. I., Sigman, M., Thomas, A. J., Schlegel, P. N., Howards, S. S., Nehra, A., Damewood, M. D., et al. (2002). Best practice policies for male infertility. Fertil. Steril. 77, 873-882.
33. Su, L., Cheng, C. Y., and Mruk, D. D. (2009). Drug transporter, P-glycoprotein (MDR1), is an integrated component of the mammalian blood-testis barrier. Int. J. Biochem. Cell Biol. 41, 2578-2587.
34. Su, L., Mruk, D. D., and Cheng, C. Y. (2011). Drug transporters, the bloodtestis barrier, and spermatogenesis. J. Endocrinol. 208, 207-223.
35. Trbovich, A. M., Martinelle, N., O'Neill, F. H., Pearson, E. J., Donahoe, P. K., Sluss, P. M., and Teixeira, J. (2004). Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Müllerian inhibiting substance. J. Steroid Biochem. Mol. Biol. 92, 199-208.
36. Van der Ven, L. T., Van de Kuil, T., Verhoef, A., Verwer, C. M., Lilienthal, H., Leonards, P. E., Schauer, U. M., Cantón, R. F., Litens, S., De Jong, F. H., et al. (2008). Endocrine effects of tetrabromobisphenol-A (TBBPA) in Wistar rats as tested in a one-generation reproduction study and a subacute toxicity study. Toxicology 245, 76-89.
37. van Herwaarden, A. E., Wagenaar, E., Merino, G., Jonker, J. W., Rosing, H., Beijnen, J. H., and Schinkel, A. H. (2007). Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol. Cell. Biol. 27, 1247-1253.
38. Wittgen, H. G., Greupink, R., van den Heuvel, J. J., van den Broek, P. H., Dinter-Heidorn, H., Koenderink, J. B., and Russel, F. G. (2012). Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists. Mol. Pharm. 9, 1351-1360.
39. Wittgen, H. G., van den Heuvel, J. J., van den Broek, P. H., Dinter-Heidorn, H., Koenderink, J. B., and Russel, F. G. (2011). Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4. Drug Metab. Dispos. 39, 1294-1302.
40. Woodward, O. M., Köttgen, A., Coresh, J., Boerwinkle, E., Guggino, W. B., and Köttgen, M. (2009). Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. U.S.A. 106, 10338-10342.